Alseres Pharmaceuticals Inactive 10-Q2003 Q1 Quarterly report

Filed: 15 May 03, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: Addendum, aggregate, antidilution, APB, applied, arrangement, asset, beneficial, beneficially, Boucher, Cap, Certificate, certification, Chapter, Chief, classified, Code, compensation, consulting, Continental, contractual, criteria, dedicated, degree, deposit, dividend, Earlier, ensure, equipment, exempt, Exhibit, favor, feature, finalized, FLUORATEC, fraud, fully, Gipson, individual, influence, Jr, lease, lesser, LLC, met, method, minimum, NASDAQ, noncancelable, opposition, percent, person, portion, preclinical, President, ProCell, ranging, recommended, relying, renewed, resale, retain, role, rosenthal, seek, Small, Snyder, solicitation, space, sublease, sublet, submit, summarize, table, Title, transfer, trust, underlying, volatility, yield

Removed: accumulated, amortized, check, David, designated, disposal, end, goodwill, Hillson, Identification, impairment, incorporation, initiated, intangible, January, mark, organization, par, past, periodic, preceding, ratable, replaced, reporting, shorter, Standard, transition

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Alseres Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 99.1

CERTIFICATION PURSUANT TO

SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Boston Life Sciences, Inc. (the “Company”), does hereby certify that to his knowledge:

the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2003 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

the information contained in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2003 fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ ROBERT J. ROSENTHAL
Robert J. Rosenthal Director, Chief Executive Officer and President


/s/ JOSEPH P. HERNON
Joseph P. Hernon Executive Vice President, Chief Financial Officer and Secretary

Dated: May 15, 2003

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.